Drugs / 68Ga-R10602
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06745804 | Dec 2024 → May 2026 | breast adenocarcinoma, hormone receptor-positive breast cancer | Radionetics Oncology | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 68Ga-R10602 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06745804 ↗ |
| Modality | Small molecule | “gallium-labeled small molecule radioligand” NCT06745804 ↗ |